Jonathon Olsburgh

Jonathon Olsburgh

Auto-generated profile, based on publicly available information

Jonathon Olsburgh

Directorate of Transplant, Renal and Urology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2015 in European Radiology
Verified
Journal Article
Closed access
PDF file
MCMarica Cutajar
Marica Cutajar
RHRachel Hilton
Rachel Hilton
JOJonathon Olsburgh
Jonathon Olsburgh
SMStephen D Marks
Stephen D Marks
DTDavid L Thomas
David L Thomas
IGIsky Gordon
Isky Gordon

1 February 2016 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JOJ. Olsburgh
J. Olsburgh
RZR. H. Zakri
R. H. Zakri
CHC. Horsfield
C. Horsfield
RCR. Collins
R. Collins
JFJ. Fairweather
J. Fairweather
GKG. Koffman
G. Koffman
We present four cases of transitional cell carcinoma of the transplant ureter (TCCtu). In three cases, localized tumor resection and a variety of reconstructive techniques were possible. Transplant nephrectomy with cystectomy was performed as a secondary treatment in one locally excised case. Transplant nephroureterectomy was performed as primary treatment in one case. The role of oncogenic viruses and genetic fingerprinting to determine the origin of TCCtu are described. Our cases and a systematic literature review illustrate the surgical, nephrological, and oncological challenges of this uncommon but important condition.

23 March 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
IUInes Ushiro-Lumb
Ines Ushiro-Lumb
CCChris Callaghan
Chris Callaghan
JPJasvir Parmar
Jasvir Parmar
JOJonathon Olsburgh
Jonathon Olsburgh
MBMarius Berman
Marius Berman
DGDale Gardiner
Dale Gardiner
We read with interest the case report by Kaul and colleagues detailing a proven case of transmission of SARS‐CoV‐2 from a lung donor with a negative nasopharyngeal swab (NPS) to a recipient in the United States (1). A surgeon who reported possible exposure to the patient’s respiratory secretions, but none of the other staff involved, also became infected.

22 July 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CCChrysanthos D Christou
Chrysanthos D Christou
FJFayyad Jaradat
Fayyad Jaradat
JOJonathon Olsburgh
Jonathon Olsburgh
SSSteven Sacks
Steven Sacks
TKTheodoros Kassimatis
Theodoros Kassimatis
Ischemia-reperfusion injury (IRI) is an unavoidable consequence of kidney transplantation and a major contributor to delayed graft function (DGF). DGF, traditionally defined as the need for dialysis within the first week post-transplant, is linked to inferior graft and patient outcomes, prolonged hospitalization, and higher health care costs. IRI begins with tissue hypoxia, which triggers an inflammatory response on reperfusion. The renal tubule plays a critical role in complement synthesis, with local activation driving inflammation and graft immunogenicity more than circulating liver-derived complement. The lectin pathway is a key initiator of complement activation in hypoxic renal tubules, primarily through collectin-11's interaction with glycan ligands on hypoxic cells, with further amplification through the alternative pathway. Despite promising preclinical results, systemic complement inhibitors have not significantly improved DGF in clinical studies, likely due to inefficient targeting of ischemic renal tubules. Machine perfusion offers a novel approach to delivering therapeutics directly to donor kidneys. Notably, hypothermic machine perfusion has improved DGF rates and early graft outcomes. Emerging targeted delivery systems using extracellular vesicles or nanoparticle-based carriers also promise to deliver therapeutics to the sites of injury. Organ-targeted complement inhibition through machine perfusion or other targeted delivery systems represent compelling strategies for IRI prevention. Finally, multigenic xenografts engineered to prevent complement activation have shown initial promise in overcoming the complement-mediated barriers that continue to challenge allotransplantation in humans.

1 June 2021 in European Urology
Verified
Journal Article
Closed access
PKP. Kotecha
P. Kotecha
ATA. Tapping
A. Tapping
BPB. Pezzack
B. Pezzack
AWA.F. Williams
A.F. Williams
LHL. Hunt
L. Hunt
RZR.H. Zakri
R.H. Zakri

1 June 2021 in European Urology
Verified
Journal Article
Closed access
RBRomain Boissier
Romain Boissier
ORO. Rodriguez-Faba
O. Rodriguez-Faba
VHV. Hevia
V. Hevia
RZR. Hassan Zakri
R. Hassan Zakri
KBKlemens Budde
Klemens Budde
ABA. Breda
A. Breda